Key clinical point: High-dose aducanumab reduced clinical decline at 78 weeks in EMERGE.
Major finding: A 22% decrease in CDR-SB scores versus baseline was reported.
Study details: Two randomized, placebo-controlled studies involving a total of 3,285 participants.
Disclosures: Biogen sponsored the EMERGE and ENGAGE studies. The authors are Biogen employees.
Haeberlein SB et al. AAN 2020, Abstract 46977.